Related Experiment Video
Updated: May 31, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer
1Department of Hematology-Oncology, Wayne State University, Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA. wozniakt@karmanos.org
Abstract:
Patients with non-small cell lung cancer (NSCLC) often present with advanced disease and cure rates are dismal with currently available treatment. Novel therapies including small molecule tyrosine kinase inhibitors and monoclonal antibodies are being developed to target angiogenesis, an essential step in tumorigenesis and metastasis. The only antiangiogenic agent currently approved for treatment of NSCLC is bevacizumab, although numerous other antiangiogenic inhibitors (e.g., sorafenib, sunitinib, cediranib, motesanib, BIBF 1120) are in clinical trials. Individualized treatment algorithms may improve patient outcomes and new evidence suggests that biomarkers may guide treatment decisions. We present an overview of the molecular pathways involved in angiogenesis, discuss clinical trials of bevacizumab and developmental antiangiogenic agents, and address the challenges of developing individualized treatment paradigms for NSCLC, particularly the use of biomarkers.
Insights
Novel antiangiogenic therapies show promise for advanced non-small cell lung cancer (NSCLC). Biomarkers may guide individualized treatment, improving outcomes for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) frequently presents at advanced stages with limited curative options.
- Angiogenesis is crucial for tumor growth and metastasis in NSCLC.
- Current treatments for NSCLC have dismal cure rates, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the molecular pathways of angiogenesis relevant to NSCLC.
- To discuss clinical trials of bevacizumab and other antiangiogenic agents in NSCLC.
- To explore the potential of biomarkers in guiding individualized NSCLC treatment.
Main Methods:
- Literature review of angiogenesis pathways in NSCLC.
- Analysis of clinical trial data for approved and investigational antiangiogenic therapies.
- Discussion of biomarker strategies for personalized NSCLC treatment.
Main Results:
- Bevacizumab is the only approved antiangiogenic agent for NSCLC.
- Numerous other antiangiogenic inhibitors are in various phases of clinical trials.
- Biomarkers show potential for tailoring antiangiogenic therapy in NSCLC.
Conclusions:
- Antiangiogenic therapies represent a significant advancement in NSCLC treatment.
- Individualized treatment algorithms incorporating biomarkers are essential for optimizing patient outcomes.
- Further research is needed to overcome challenges in developing and implementing biomarker-guided NSCLC therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers